ProjectAuswertung und Veröffentlichung der STudie "Pro-Symbioflor bei Reizdarmsyndrom"

Basic data

Auswertung und Veröffentlichung der STudie "Pro-Symbioflor bei Reizdarmsyndrom"
01/12/2018 to 30/06/2020
Abstract / short description:
The drug company Symbiopharm had conducted a randomized, placebo-controlled trial of a probiotic product (Pro-Symbioflor) in > 350 patients with irritable bowel syndrome (IBS) betqween 2014 and 2018. The results of this study were submitted to BfArM for marketing approval (Nachzulassung). The data of this study are to evaluated and publish under three points of view: a) global effecacy, b) analysis of drop-outs; c) analysis of placebo responders.

Involved staff


Faculty of Medicine
University of Tübingen

Local organizational units

Internal Medicine Department VI
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine


Herborn, Hessen, Germany

will be deleted permanently. This cannot be undone.